Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

“IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

The latest analyst rating for Imunon (NASDAQ:IMNN) was provided by D. Boral Capital, and Imunon maintained their buy rating. Analysts arrive at stock ratings after doing extensive research ...

Imunon management emphasized the initiation of the OVATION 3 Phase III trial as a critical milestone, with a strategy targeting early readout in HRD-positive patients that could lower overall ...

The first trial site is Washington University School of Medicine, and IMUNON is currently initiating additional trial sites and working with investigators to begin enrolling study participants.

"IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered ...